Acquisition Announced
Eli Lilly acquisition of Calytrix Bio
US$1.5bn consideration
Announced 2026 (approx.)
Advisers
Eli Lilly
Acquirer
Not disclosed
- Target
- Calytrix Bio
- Acquirer
- Eli Lilly
- Buyer based in
- United States
- Sector
- Biotech
In the league tables
Similar deals
- Lilly acquisition of Vaccine Company May 2026 · US$1.6bn · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- DT Cloud Star Acquisition and PrimeGen US merger Feb 2026 · US$1.5bn · Biotech
- Gilead acquisition of Ouro Medicines Mar 2026 · US$1.7bn · Biotech
- Eli Lilly acquisition of Curevo Vaccine May 2026 · US$1.5bn · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Calytrix Bio on its sale to Eli Lilly centerviewpartners.com
